Long-term results of intravitreal bevacizumab (avastin) injection in the treatment of macular edema secondary to branch retinal vein occlusion Retina ven dal tikanikliǧina baǧli makula ödeminde i̇ntravitreal bevacizumab (avastin) enjeksiyonunun uzun dönem sonuçlari


KÜSBECİ T., Inan Ü. Ü., Yavaş G., Inan S., Tümer E., Ermiş S. S.

Retina-Vitreus, cilt.17, sa.2, ss.88-92, 2009 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2009
  • Dergi Adı: Retina-Vitreus
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.88-92
  • Anahtar Kelimeler: Bevacizumab, Branch retinal vein occlusion, Intravitreal injection
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate the long-term effects of intravitreal bevacizumab injection in patients with macular edema secondary to branch retinal vein occlusion. Materials and Methods: In this retrospective interventional case series, 20 eyes of 20 patients with macular edema secondary to branch retinal vein occlusion for 6 months or more were treated with intravitreal bevacizumab (1.25 mg/0.05 mL). Standardized ophthalmic evaluation, best corrected visual acuity (BCVA) measurement with ETDRS chart, and fundus fluorescein angiography (FFA) were performed at baseline, at 1 month and 3 months, and at 3-month intervals thereafter. Intravitreal bevacizumab injection was repeated in recurring macular edema. The follow-up period was 18 months. Results: No ocular toxicity or adverse effects were observed. The mean number of injections per patient was 2.35±0.9. At baseline mean BCVA was logMAR 1.18±0.7 and improved to 0.62±0.5 after 1 month (p=0.002), 0.61±0.5 at 3 months (p=0.001), 0.66±0.5 at 6 months (p=0.003), 0.67±0.5 at 12 months (p=0.003), and 0.57±0.4 (p=0.006) at 18 months. In 13 eyes, VA increased 2 or more lines. FFA showed a complete or partial decrease in macular edema in all eyes after baseline injections and the same favorable response was obtained after re-injections in cases of recurrences. Conclusion: Intravitreal injection of bevacizumab appears to result in a significant improvement in visual acuity and angiographic findings in patients with macular edema secondary to branch retinal vein occlusion during a follow-up of 18 months.